UBS’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

UBS’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$2.53M	Sell	72,267 -22,528	-24%	-$772K	﹤0.01%	2680
2014 Q2	$3.12M	Buy	94,795 +2,451	+3%	+$83.9K	﹤0.01%	2434
2014 Q1	$3.4M	Buy	92,344 +13,278	+17%	+$487K	﹤0.01%	2224
2013 Q4	$3.03M	Sell	79,066 -7,768	-9%	-$245K	﹤0.01%	2381
2013 Q3	$2.38M	Buy	86,834 +2,615	+3%	+$62K	﹤0.01%	2415
2013 Q2	$1.77M	Buy	+84,219	New	+$1.64M	﹤0.01%	2680

Other funds holding WX

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS's WX Position: Q3 2014 in Review

UBS reduced its WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) stake by 24% in Q3 2014, selling an estimated $772K and leaving 72,267 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2680.

UBS first reported a position in WX in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.4M in Q1 2014. 157 funds tracked by Wall St. Rank hold WX as of Q3 2014.

UBS held 72,267 shares of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS worth $2.53M as of Q3 2014.
UBS sold 22,528 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q3 2014, an estimated $772K.
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2680 holding.
UBS first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and has held it in 6 quarters since.
UBS's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $3.4M in Q1 2014.
157 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.